罗伯特·M·戴维斯
Robert M Davis
领导U.S.大型Pharmaceuticals企业运营
专业领域
Healthcare management, life sciences
核心贡献
领导U.S.大型Pharmaceuticals企业运营
Leading large-scale Pharmaceuticals operations in U.S.
最新观点
-
戴维斯在2026年第三季度业绩中表示,以科学为主导的战略正在改变公司业务;在ESMO 2026大会上公布的肿瘤学进展——包括抗体偶联药物sac-TMT的新数据以及治疗性癌症疫苗首次三期验证——进一步降低了后期管线长期机会的临床风险;多个治疗领域的积极势头让他更有信心为患者和股东创造长期价值。当季全球销售额181亿美元。
Our science-led strategy is transforming our business. The potentially practice-changing advances in oncology research presented at the ESMO Congress 2026 further clinically de-risk the substantial long-term opportunity of our late-phase pipeline. With positive momentum across multiple therapeutic areas, I'm increasingly confident in our ability to deliver long-term value for patients and shareholders.
-
默沙东董事长兼CEO戴维斯在2026年Q3业绩中表示,公司的科学驱动战略正在重塑业务:Q3全球销售额181亿美元,肿瘤与动物保健持续强劲;在ESMO 2026公布的肿瘤研究进展进一步从临床层面降低了后期管线长期机会的风险,多个治疗领域的积极势头让他对公司为患者和股东创造长期价值的能力更有信心。
Our science-led strategy is transforming our business. The potentially practice-changing advances in oncology research presented at the ESMO Congress 2026 further clinically de-risk the substantial long-term opportunity of our late-phase pipeline. With positive momentum across multiple therapeutic areas, I'm increasingly confident in our ability to deliver long-term value for patients and shareholders.
-
默克CEO戴维斯称,科学驱动的战略正在改变公司业务;ESMO 2026公布的多项肿瘤学进展从临床上降低了晚期管线的长期机会风险,多个治疗领域积极势头让他对长期为患者和股东创造价值更有信心。
Our science-led strategy is transforming our business. The potentially practice-changing advances in oncology research presented at the ESMO Congress 2026 further clinically de-risk the substantial long-term opportunity of our late-phase pipeline. With positive momentum across multiple therapeutic areas, I'm increasingly confident in our ability to deliver long-term value for patients and shareholders.